BioMarin Pharmaceutical | BMRN - Debt


BioMarin Pharmaceutical reported $1.44B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amgen USD 54.6B 17M Dec/2025
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Gilead Sciences USD 24.94B 5M Dec/2025
Incyte USD 39.43M 982K Mar/2026
Insmed USD 727.62M 275K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Moderna USD 1.31B 571M Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 20.02B 1.73B Mar/2026
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026